Data in Fig. 7 demonstrate that SDT can significantly diminish CD8+(CD4−)CTLA-4+ Treg population, not only in primary tumours, in which it accounts for almost a three-fold decrease in percentage, but also by a two-fold decrease in distant tumours. The gene discussed is CD8A; the disease is neoplasm.